Business Context and Reporting Period
Company: Bristol-Myers Squibb Company
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2003
Overview: The Company reported significant year-over-year improvements in sales and earnings, driven by strong prescription demand for key brands (PLAVIX*, PRAVACHOL, ABILIFY*) and the absence of the massive litigation and asset impairment charges recorded in the prior year. The Company is actively managing the workdown of wholesaler inventories previously accounted for under a consignment model.
Key Financial Metrics
| Metric (in millions) | Q3 2003 | Q3 2002 | 9M 2003 | 9M 2002 |
|---|---|---|---|---|
| Net Sales | $5,337 | $4,537 | $15,100 | $13,325 |
| Net Earnings | $884 | $357 | $2,523 | $1,692 |
| Diluted EPS (Continuing Ops) | $0.45 | $0.17 | $1.30 | $0.85 |
| Operating Cash Flow (9M) | $2,260 (2003) vs $257 (2002) | |||
| Cash & Equivalents | $4,953 (Sep 30, 2003) | |||
| Long-Term Debt | $7,421 (Sep 30, 2003) | |||
| Working Capital | $3,754 (Sep 30, 2003) |
Note: Margins improved significantly as a percentage of sales due to the absence of $948 million in litigation and impairment charges recorded in Q3 2002.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18% in Q3 and 13% for the nine months, driven by volume growth (13% in Q3), favorable foreign exchange, and price increases. The Pharmaceuticals segment contributed the majority of this growth.
- Earnings Recovery: Net earnings from continuing operations increased 161% in Q3 and 52% for the nine months. This is primarily attributable to the absence of the $569 million BUSPAR/TAXOL litigation settlement charge and the $379 million ImClone asset impairment charge recorded in Q3 2002.
- Cash Flow: Operating cash flow surged to $2.26 billion for the nine months ended Sep 30, 2003, compared to $257 million in the prior year. The 2002 figure was depressed by a $2.0 billion tax payment related to the Clairol sale.
- Debt Structure: Long-term debt increased to $7.4 billion from $6.3 billion at year-end 2002, largely due to $1 billion in notes issued in August 2003. Subsequent to the period, the Company issued an additional $1.2 billion in convertible debentures.
Guidance, Outlook, and Risks
Management Commentary and Guidance
- 2003 Outlook: Management expects full-year 2003 non-GAAP fully diluted EPS to be between $1.68 and $1.73. GAAP EPS guidance is $1.65 to $1.70, factoring in expected restructuring charges and licensing payments.
- Q4 Expectations: The fourth quarter is expected to be weaker than the third due to higher R&D spending and the loss of exclusivity for SERZONE, MONOPRIL, GLUCOPHAGE*XR (U.S.), and TAXOL* (Europe).
- Future Challenges: The Company anticipates annual exclusivity losses of approximately $1 billion in net sales over the next several years, which may pressure margins as high-margin products face generic competition.
Risks and Contingencies
- Litigation: Significant pending matters include antitrust litigation regarding TAXOL* and BUSPAR (settlements pending final court approval), securities class actions regarding ImClone and wholesaler inventory practices, and product liability suits involving PPA, SERZONE, and STADOL NS.
- Regulatory: Ongoing investigations by the SEC and U.S. Attorney's Office regarding sales incentives, inventory levels, and accounting practices. Additionally, the Company faces environmental directives in New Jersey regarding the Passaic River.
- Internal Controls: The Company acknowledged two "material weaknesses" in internal controls identified by auditors in 2002 but concluded that disclosure controls were effective as of September 30, 2003, following remediation efforts.
Investor Verification Checklist
- Settlement Finality: Verify the final court approval status of the $135 million TAXOL* and $535 million BUSPAR antitrust settlements, as final approval hearings were scheduled for Q4 2003.
- Wholesaler Inventory: Monitor the completion of the "orderly workdown" of consignment inventory held by major wholesalers (Cardinal and McKesson), expected to be substantially complete by year-end 2003.
- Exclusivity Losses: Track the impact of generic competition entering the market for TAXOL* (Europe), GLUCOPHAGE*XR, and SERZONE in Q4 2003 and beyond.
- Legal Investigations: Follow developments in the SEC and Department of Justice investigations regarding sales incentives and accounting practices, which could result in fines or restatements.
- Debt Ratings: Note the recent credit rating downgrades by Standard & Poor's (to AA-) and Moody's (to A1) and monitor future debt issuance costs.